恩度联合XELIRI方案二线治疗转移性结直肠癌初步临床观察.pdfVIP

2010;30(4) 南方医科大学学报(J South Med Univ) • 813 • 恩度联合XELI阳方案二线治疗转移性结直肠癌初步临床观察 廖旺军，中鹏，吴文韵，石敏，罗荣城(南方医科大学南方医院肿瘤科，广东广州 510515) 摘要:目的观察恩度联合 XELIRI 方案二线治疗晚期结直肠癌的近期疗效及毒副反应。方法对21 例草酸铅治疗失败 2 2 的晚期结宣肠癌给予 XELIRI 方案(希罗达 1.0mglm ， 2 次 Id ， 口服， 1-14d; 伊立替康 250 mglm ，静滴，第 1 天联合恩度 治疗，恩度剂量为 15 mg/d ，连用 14 d ，每 21 天重复。 2 周期后按 RECIST 评价标准评价近期疗效、NCI-CTCAE3.0 标准 评价毒副反应。结果客观有效率为 9.5%，中位疾病进展时间为 3.9 月。主要毒副反应为骨髓抑制、周围神经毒性及胃 肠道反应。结论恩度联合 XELIRI 方案是晚期结直肠癌安全、有效的二线治疗方案。 关键词:结直肠癌;恩度:希罗达;伊立替康 中图分类号:R735.3 文献标识码:A 文章编号: 1673-4254(2010)04-0813-02 Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer LIAOWang才un， SHEN Peng, WU Wen 泸m， SHI Min , LUO Rong-cheng Department of Oncology, Nanfang Hospital , Southern Medical Univers坷， Gωngzhou 510515, China Abstract: Objec创刊 To evaluate the short-term e伍cacyand ωxicity of endostar in cornbination with XELIRI as the second-line treatrnent for advanced colorectal canc町. Methods Twenty咱ne patients wi也 advanced colorectal cancer were 2 treated with intravenous infusion ofendostar (1 5 mglday for 14 consecutive days) and irinotecan (250 mglm , single dose on 2 伽e first day), and oral administration of capecitabine (1.0 mglm , twice daily for 14 days), and the treatrnent cycle was r叩ea饨d every 21 days. The efficacy and ωxicity of the treatrnents were evaluated according 10 RECIST and NCI-CTCAE3.0 standard, respectively. Results The overall response rate was 9.5% in these patients , with a median time ωprogression (rnTTP) of 3.9 rnon